MAPT and proteostasis deficiencies: It is hopefully possible that further knowledge of the molecular mechanisms through which tau and synuclein act physiologically and pathologically on NMDARs and AMPARs will aid researchers in the identification and preclinical evaluation of new molecules capable of restoring the functionality of glutamatergic transmission in the early stages of proteinopathies.